{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T03:44:00Z","timestamp":1790048640833,"version":"4.0.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,20]],"date-time":"2021-11-20T00:00:00Z","timestamp":1637366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,20]],"date-time":"2021-11-20T00:00:00Z","timestamp":1637366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Patients with peritoneal dissemination (PD) caused by abdominal malignancies are often associated with massive ascites, which shows extremely dismal prognosis because of the discontinuation of systemic chemotherapy mostly due to poor performance status. Many treatment methods, such as simple drainage, peritoneovenous shunting (PVS) and cell-free and concentrated reinfusion therapy (CART), have been used for symptom relief. However, the clinical efficacies of these methods have not been fully investigated yet. Recently, we developed the Clinical Practice Guideline for PD caused by various malignancies according to \"Minds Clinical Practice Guideline Development Guide 2017\". In this guideline, we systematically reviewed information on clinical diagnosis and treatments for PD using PubMed databases (2000\u2009\u2013\u20092020), and clarified the degree of recommendation for clinical questions (CQ). The evidence level was divided into groups by study design and quality. The literature level and a body of evidence were evaluated in reference to the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) system. Based on the results of systematic review, the strength of the recommendations was evaluated at a consensus meeting of the Guideline Committee. This is the English synopsis of the part of treatment of malignant ascites in Clinical Practice Guideline for PD, 2021 in Japanese. The guidelines summarize the general aspect of the treatment of malignant ascites and statements with recommendation strengths, evidence levels, agreement rates and future perspective for four raised clinical questions.<\/jats:p>","DOI":"10.1007\/s10147-021-02077-6","type":"journal-article","created":{"date-parts":[[2021,11,20]],"date-time":"2021-11-20T06:02:45Z","timestamp":1637388165000},"page":"1-6","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Clinical practice guideline for the treatment of malignant ascites: section summary in Clinical Practice Guideline for peritoneal dissemination (2021)"],"prefix":"10.1007","volume":"27","author":[{"given":"Keisuke","family":"Matsusaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuniaki","family":"Aridome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigenobu","family":"Emoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Kajiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobumasa","family":"Takagaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Tsubamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoji","family":"Nagao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5708-7130","authenticated-orcid":false,"given":"Joji","family":"Kitayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,20]]},"reference":[{"key":"2077_CR1","unstructured":"Kojimahara N NT, Morizane T, Yamaguchi N, Yoshida M (eds) (2017) Japan Council for Quality Health Care. Minds Manual for Guideline Development 2017 Japan Council for Quality Health CarePublishing PhysicsWeb. https:\/\/minds.jcqhc.or.jp\/docs\/various\/manual_2017\/pdf\/manual_all_2017.pdf"},{"key":"2077_CR2","unstructured":"Japanese Society for Palliative Medicine Guidelines (2017) Guidelines for Alleviation of Gastrointestinal Symptoms of Cancer Patients. Kanehara, Tokyo"},{"issue":"6","key":"2077_CR3","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/s0002-9610(06)80078-4","volume":"159","author":"DW Weaver","year":"1990","unstructured":"Weaver DW, Wiencek RG, Bouwman DL (1990) Percutaneous Denver peritoneovenous shunt insertion. Am J Surg 159(6):600\u2013601. https:\/\/doi.org\/10.1016\/s0002-9610(06)80078-4","journal-title":"Am J Surg"},{"issue":"5","key":"2077_CR4","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1007\/s00270-010-0057-y","volume":"34","author":"S Sugawara","year":"2011","unstructured":"Sugawara S, Sone M, Arai Y et al (2011) Radiological insertion of Denver peritoneovenous shunts for malignant refractory ascites: a retrospective multicenter study (JIVROSG-0809). Cardiovasc Intervent Radiol 34(5):980\u2013988. https:\/\/doi.org\/10.1007\/s00270-010-0057-y","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"5","key":"2077_CR5","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1007\/BF02303809","volume":"1","author":"DL Schumacher","year":"1994","unstructured":"Schumacher DL, Saclarides TJ, Staren ED (1994) Peritoneovenous shunts for palliation of the patient with malignant ascites. Ann Surg Oncol 1(5):378\u2013381. https:\/\/doi.org\/10.1007\/BF02303809","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"2077_CR6","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1002\/1097-0142(20010401)91:7<1247::aid-cncr1125>3.0.co;2-w","volume":"91","author":"SC Bieligk","year":"2001","unstructured":"Bieligk SC, Calvo BF, Coit DG (2001) Peritoneovenous shunting for nongynecologic malignant ascites. Cancer 91(7):1247\u20131255. https:\/\/doi.org\/10.1002\/1097-0142(20010401)91:7%3c1247::aid-cncr1125%3e3.0.co;2-w","journal-title":"Cancer"},{"issue":"39","key":"2077_CR7","first-page":"794","volume":"48","author":"RH Hu","year":"2001","unstructured":"Hu RH, Lee PH (2001) Salvaging procedures for dysfunctional peritoneovenous shunt. Hepatogastroenterology 48(39):794\u2013797","journal-title":"Hepatogastroenterology"},{"key":"2077_CR8","first-page":"1628","volume":"37","author":"Y Yamazaki","year":"1975","unstructured":"Yamazaki Y (1975) Infusion of concentrated ascites after filtration of bacteria and tumor cells (Japanese). Geka 37:1628\u20131629","journal-title":"Geka"},{"issue":"4","key":"2077_CR9","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s10147-011-0199-1","volume":"16","author":"K Matsusaki","year":"2011","unstructured":"Japanese CSG, Matsusaki K, Ohta K et al (2011) Novel cell-free and concentrated ascites reinfusion therapy (KM-CART) for refractory ascites associated with cancerous peritonitis: its effect and future perspectives. Int J Clin Oncol 16(4):395\u2013400. https:\/\/doi.org\/10.1007\/s10147-011-0199-1","journal-title":"Int J Clin Oncol"},{"issue":"10","key":"2077_CR10","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1111\/aor.13691","volume":"44","author":"K Matsusaki","year":"2020","unstructured":"Matsusaki K, Orihashi K (2020) Feasibility, efficacy, and safety of cell-free and concentrated ascites reinfusion therapy (KM-CART) for malignant ascites. Artif Organs 44(10):1090\u20131097. https:\/\/doi.org\/10.1111\/aor.13691","journal-title":"Artif Organs"},{"key":"2077_CR11","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1186\/s40064-015-1508-3","volume":"4","author":"Y Kimura","year":"2015","unstructured":"Kimura Y, Harada Y, Yasuda N et al (2015) Effective recovery of highly purified CD326(+) tumor cells from lavage fluid of patients treated with a novel cell-free and concentrated ascites reinfusion therapy (KM-CART). Springerplus 4:780. https:\/\/doi.org\/10.1186\/s40064-015-1508-3","journal-title":"Springerplus"},{"issue":"23","key":"2077_CR12","doi-asserted-by":"publisher","first-page":"4036","DOI":"10.12998\/wjcc.v7.i23.4036","volume":"7","author":"T Anayama","year":"2019","unstructured":"Anayama T, Taguchi M, Tatenuma T et al (2019) In-vitro proliferation assay with recycled ascitic cancer cells in malignant pleural mesothelioma: a case report. World J Clin Cases 7(23):4036\u20134043. https:\/\/doi.org\/10.12998\/wjcc.v7.i23.4036","journal-title":"World J Clin Cases"},{"issue":"7","key":"2077_CR13","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.21873\/anticanres.11730","volume":"37","author":"M Nagasato","year":"2017","unstructured":"Nagasato M, Rin Y, Yamamoto Y et al (2017) A tumor-targeting adenovirus with high gene-transduction efficiency for primary pancreatic cancer and ascites cells. Anticancer Res 37(7):3599\u20133605. https:\/\/doi.org\/10.21873\/anticanres.11730","journal-title":"Anticancer Res"},{"key":"2077_CR14","doi-asserted-by":"publisher","first-page":"491","DOI":"10.2147\/OTT.S43287","volume":"6","author":"A Ueda","year":"2013","unstructured":"Ueda A, Hosokawa A, Ogawa K et al (2013) Treatment outcome of advanced pancreatic cancer patients who are ineligible for a clinical trial. Onco Targets Ther 6:491\u2013496. https:\/\/doi.org\/10.2147\/OTT.S43287","journal-title":"Onco Targets Ther"},{"issue":"7","key":"2077_CR15","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.ejso.2015.04.013","volume":"41","author":"H Yamaguchi","year":"2015","unstructured":"Yamaguchi H, Kitayama J, Emoto S et al (2015) Cell-free and concentrated ascites reinfusion therapy (CART) for management of massive malignant ascites in gastric cancer patients with peritoneal metastasis treated with intravenous and intraperitoneal paclitaxel with oral S-1. Eur J Surg Oncol 41(7):875\u2013880. https:\/\/doi.org\/10.1016\/j.ejso.2015.04.013","journal-title":"Eur J Surg Oncol"},{"issue":"4","key":"2077_CR16","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s10120-020-01043-x","volume":"23","author":"TE Nakajima","year":"2020","unstructured":"Nakajima TE, Yamaguchi K, Boku N et al (2020) Randomized phase II\/III study of 5-fluorouracil\/l-leucovorin versus 5-fluorouracil\/l-leucovorin plus paclitaxel administered to patients with severe peritoneal metastases of gastric cancer (JCOG1108\/WJOG7312G). Gastric Cancer 23(4):677\u2013688. https:\/\/doi.org\/10.1007\/s10120-020-01043-x","journal-title":"Gastric Cancer"},{"issue":"12","key":"2077_CR17","doi-asserted-by":"publisher","first-page":"5861","DOI":"10.1007\/s00520-020-05401-4","volume":"28","author":"Y Nagata","year":"2020","unstructured":"Nagata Y, Kato K, Miyamoto T et al (2020) Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) in gastrointestinal cancer patients with massive ascites treated with systemic chemotherapy. Support Care Cancer 28(12):5861\u20135869. https:\/\/doi.org\/10.1007\/s00520-020-05401-4","journal-title":"Support Care Cancer"},{"issue":"1","key":"2077_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00003088-200038010-00001","volume":"38","author":"F Levi","year":"2000","unstructured":"Levi F, Metzger G, Massari C et al (2000) Oxaliplatin: pharmacokinetics and chronopharmacological aspects. Clin Pharmacokinet 38(1):1\u201321. https:\/\/doi.org\/10.2165\/00003088-200038010-00001","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"2077_CR19","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/j.1349-7006.2006.00166.x","volume":"97","author":"H Minami","year":"2006","unstructured":"Minami H, Kawada K, Sasaki Y et al (2006) Pharmacokinetics and pharmacodynamics of protein-unbound docetaxel in cancer patients. Cancer Sci 97(3):235\u2013241. https:\/\/doi.org\/10.1111\/j.1349-7006.2006.00166.x","journal-title":"Cancer Sci"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-021-02077-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-021-02077-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-021-02077-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T22:13:56Z","timestamp":1641420836000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-021-02077-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,20]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["2077"],"URL":"https:\/\/doi.org\/10.1007\/s10147-021-02077-6","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,20]]},"assertion":[{"value":"1 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no potential conflicts of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}